In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Lung ultrasound may reduce heart failure hospitalizations: preliminary results from the LUS-HF trial.

Session Heart failure prognosis and the options to improve

Speaker Mercedes Rivas Lasarte

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Treatment
  • Session type : Rapid Fire Abstracts

Authors : M Rivas-Lasarte (Barcelona,ES), A Maestro Benedicto (Barcelona,ES), J Fernandez Martinez (Barcelona,ES), J Alvarez-Garcia (Barcelona,ES), E Sole Gonzalez (Barcelona,ES), L Lopez Lopez (Barcelona,ES), S Mirabet (Barcelona,ES), A Sionis (Barcelona,ES), E Roig Minguell (Barcelona,ES), J Cinca Cuscullola (Barcelona,ES)

Authors:
M Rivas-Lasarte1 , A Maestro Benedicto1 , J Fernandez Martinez1 , J Alvarez-Garcia1 , E Sole Gonzalez1 , L Lopez Lopez1 , S Mirabet1 , A Sionis1 , E Roig Minguell1 , J Cinca Cuscullola1 , 1Hospital de la Santa Creu i Sant Pau, Cardiology Department - Barcelona - Spain ,

On behalf: LUS-HF investigators

Citation:

Background
Pulmonary congestion is expressed in the form of B-lines detected by lung ultrasound (LUS), which has proven to be a potent prognostic predictor of hospitalization and mortality in HF. However, it is still unknown if a treatment strategy guided by LUS in HF patients may improve outcomes.

Purpose
The objective of our study is to analyze whether a treatment guided by LUS in patients with HF reduces the combined endpoint of readmission for HF worsening or death in a 6-month follow-up.

Methods
LUS-HF (NCT02959372 at ClinicalTrials.gov) is a randomized, single center, simple blind clinical trial that enrolls patients older than 18 years who have been hospitalized for HF. The exclusion criteria are life expectancy less than 6 months or severe lung disease. Eligible patients are randomized into either the "LUS group" or the "control group". The follow-up consists of visits in the HF clinic at periods of 15 days, 1, 3, and 6 months after discharge. Both groups are examined with LUS, but the result of the test is only provided to the treating physician in the "LUS group".

Results
Clinical characteristics of the first 52 patients included are summarized in the table. The primary endpoint occurred in the 42.3% of the "control group" versus 19.2% of the "LUS group" (log-rank test 0.077, figure).

Conclusions:
According to the preliminary results of the LUS-HF trial, LUS guided treatment may reduce readmissions in HF patients.

Control group

(n=26)

LUS group (n=26)

P value

Age (years), × (DE)

69.8(13)

69.8(13)

0.98

Male, n (%)

20(77)

21(81)

0.73

HFrEF, n (%)

16 (62)

15(58)

0.54

HFmrEF, n (%)

4 (15)

7 (27)

HFpEF, n (%)

6 (23)

4 (15)

Diabetes, n (%)

13 (50)

11 (42)

0.58

Renal insufficiency*, n (%)

13 (50)

10 (38)

0.40

NT-proBNP **(ng/L), x (DE)

3511 (3595)

3523 (4872)

0.99

Number of B lines**, x (DE)

5.0 (4.3)

5.4 (4.4)

0.70

Readmissions

10 (38.5)

5 (19.2)

0.13

Death

1 (3.9)

2(7.7)

0.55

*Creatinine clearance<60ml/kg/1.73m2. ** The day of discharge LUS: lung ultrasound; HF heart failure; rEF: reduced ejection fraction (<40%); mrEF: mild reduced ejection fraction (40-49); pEF: preserved ejection fraction

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are